{"id":"W2339800992","doi":"10.1200/jco.2006.24.18_suppl.3054","title":"Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mucositis; Tolerability; Neutropenia; Internal medicine; Gastroenterology; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Carboplatin; Toxicity; Phases of clinical research; Surgery; Chemotherapy; Adverse effect; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001935135,0.001638332,0.002198318,0.0003901177,0.0007112761,0.000981465,0.0009323411,0.001347846,0.002705188],"category_scores_gemma":[0.00108822,0.0006329818,0.001185684,0.0003747912,0.0009363569,0.000593259,0.0002964824,0.002645837,0.0007455379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001238539,"about_ca_system_score_gemma":0.002143467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002906285,"about_ca_topic_score_gemma":0.005380759,"domain_scores_codex":[0.9993706,0.0002863063,0.00003652087,0.00008012649,0.00006564477,0.0001607142],"domain_scores_gemma":[0.9991266,0.0001470238,0.0001020398,0.0000618058,0.00009017613,0.0004723044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7071753,0.09269938,0.01202488,0.001011434,0.002694626,0.0009706764,0.0005624564,0.003824703,0.09316373,0.0002180005,0.008087941,0.07756689],"study_design_scores_gemma":[0.3968016,0.5659049,0.02464247,0.00002799992,0.0009252261,0.0003920725,0.00004784494,0.0008291866,0.006335455,0.0001481372,0.00390394,0.00004117826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893161,0.001785629,0.0006733554,0.0003971119,0.00009789526,0.003585752,0.001999108,0.00009103146,0.002054126],"genre_scores_gemma":[0.9849225,0.001443822,0.00179545,0.0008303589,0.000137214,0.002329663,0.005248488,0.00004277383,0.003249671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002906285,"threshold_uncertainty_score":0.01023412,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07360003561611962,"score_gpt":0.4515215525426398,"score_spread":0.3779215169265202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}